Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LEI105
Cat. No.:
OB0425LY-041
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
LEI105 is an active and highly selective dual diacylglycerol lipase (DAGL)-α/DAGL-β inhibitor.
Synonyms:
1800327-36-9; 1-[6-(4-Methylphenyl)-[1,3]oxazolo[4,5-b]pyridin-2-yl]-6-phenylhexan-1-one; 6-Phenyl-1-(6-(p-tolyl)oxazolo[4,5-b]pyridin-2-yl)hexan-1-; 6-Phenyl-1-(6-(p-tolyl)oxazolo[4,5-b]pyridin-2-yl)hexan-1- one
CAS No.:
1800327-36-9
Compound CID:
122390213
Formula:
C25H24N2O2
Formula Weight:
384.47
Specification
Target:
DAGL
Pathway:
Metabolic enzyme/Protease
Storage:
Storage at -20°C.
Applications:
LEI105 is primarily used in inflammation, metabolic diseases and some cancer research.
